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Abstract
Barrett’s esophagus (BE) is an important condition 
given its significant premalignant potential and dismal 
five-year survival outcomes of advanced esophageal 
adenocarcinoma. It is therefore suggested that patients 
with a diagnosis of BE undergo regular surveillance 
in order to pick up dysplasia at an earlier stage to 
improve survival. Current “gold-standard” surveillance 
protocols suggest targeted biopsy of visible lesions 
followed by four quadrant random biopsies every 2 
cm. However, this method of Barrett’s surveillance 
is fraught with poor endoscopist compliance as the 
procedures are time consuming and poorly tolerated by 
patients. There are also significant miss-rates with this 
technique for the detection of neoplasia as only 13% 
of early neoplastic lesions appear as visible nodules. 
Despite improvements in endoscope resolution these 
problems persist. Chromoendoscopy is an extremely 
useful adjunct to enhance mucosal visualization and 
characterization of Barrett’s mucosa. Acetic acid 
chromoendoscopy (AAC) is a simple, non-proprietary 
technique that can significantly improve neoplasia 
detection rates. This topic highlight summarizes the 
current evidence base behind AAC for the detection 
of neoplasia in BE and provides an insight into the 
direction of travel for further research in this area.
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Core tip: Neoplasia detection in surveillance of Barrett’s 
esophagus (BE) remains challenging as current gold-
standard four quadrant biopsies have a high miss-rate 
and are poorly adhered to. Evidence to support the 
use of acetic acid chromoendoscopy (AAC) is growing. 
We discuss the current evidence of AAC in BE and the 
direction of travel for future research.
MINIREVIEWS
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i25.5753
5753 July 7, 2016|Volume 22|Issue 25|WJG|www.wjgnet.com
World J Gastroenterol  2016 July 7; 22(25): 5753-5760
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
Chedgy FJQ, Subramaniam S, Kandiah K, Thayalasekaran S, 
Bhandari P. Acetic acid chromoendoscopy: Improving neoplasia 
detection in Barrett’s esophagus. World J Gastroenterol 2016; 
22(25): 5753-5760  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i25/5753.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i25.5753
INTRODUCTION
The incidence of esophageal cancer is increasing[1], 
representing the ninth most common cancer in the 
United Kingdom. Seven thousand and eight hundred 
people are diagnosed with the condition every year, 
and it accounts for 5% of all cancer deaths in the 
United Kingdom[2]. It is well recognized that Barrett’s 
esophagus (BE) is a significant risk factor for the deve­
lopment of esophageal adenocarcinoma (EAC) and is 
present in 1.6% of the general population[3] and in up 
to 20% of patients with gastroesophageal reflux[4].
BE is defined as an esophagus in which any portion 
of the normal distal squamous epithelial lining has 
been replaced by metaplastic columnar epithelium, 
which is clearly visible endoscopically above the gastro­
esophageal junction[5]. It is universally recognized 
that the presence of intestinal metaplasia (IM) confers 
an increased risk of developing Barrett’s­related EAC 
and that IM is present in the vast majority of long­
segment Barrett’s[6]. The development of Barrett’s 
EAC is postulated to occur in a progressive fashion 
from IM to low grade dysplasia (LGD) to high grade 
dysplasia (HGD) and then EAC. The annual rate of 
transformation into EAC in patients with non­dysplastic 
BE is estimated to be between 0.07% and 0.82%[7­9]. 
However, the annual rate of progression from LGD to 
HGD or EAC is as high as 8.8% as demonstrated by 
the recent SURF trial[10] and from HGD to EAC is 12% 
to 40%[11,12]. The aim of endoscopic surveillance is to 
alter the natural history of the disease by identifying 
neoplasia at an earlier stage and thus instituting 
curative endoscopic therapy.
Established surveillance protocols suggest taking 
targeted biopsies of visible lesions and random four 
quadrant biopsies (4QBS) every 2 cm (Cleveland 
protocol) which reportedly proffers the maximum 
yield of dysplasia in comparison with other biopsy 
protocols[13]. However, there are several drawbacks 
to this technique. With only 13% of early neoplastic 
lesions appearing as visible nodules[14], a significant 
proportion of Barrett’s neoplasia is not visible on high­
definition white­light endoscopy alone, with reported 
sensitivity in the range 40%­64% and specificity 
98%­100%[15]. These non­visible neoplastic foci can 
occupy areas as small as 0.5 cm2[16]. Unsurprisingly, 
there is a significant miss­rate with 4QBS. Studies 
comparing 4QBS with surgical resection specimen 
have shown that 41%­66% of dysplastic lesions 
are missed by 4QBS[17,18]. The total mucosal surface 
sampled with 4QBS is equivalent to 0.5 cm2 equating 
to sampling of only 3.5% of an average­length BE. 
4QBS are notoriously poorly adhered to[19], with worse 
adherence for longer segments, further compounding 
miss­rates. In addition, 4QBS are time­consuming and 
poorly tolerated by patients. The cost of processing 
4QBS is significant, with each cassette of tissue costing 
£58.90 ($90.61) to process[20].
These pitfalls in surveillance have prompted eva­
luation of more effective techniques to improve the 
diagnostic accuracy for the detection of IM and early 
Barrett’s neoplasia, the most promising of which is 
acetic acid chromoendoscopy (AAC). This review aims 
to summarize the current evidence for AAC in BE and 
provide insight into the direction of travel for further 
research in this area.
ACETIC ACID MECHANISM OF ACTION
The use of acetic acid (AA) in the digestive tract 
was first reported by Guelrud and Herrera[21], to aid 
in the identification of small islands of BE following 
ablative therapy. The technique was derived from 
gynecology where AA instilled onto the cervix has been 
used to highlight dysplastic areas during screening 
for cervical intraepithelial neoplasia[22]. When AA 
is sprayed onto squamous epithelium, there is an 
acetowhitening reaction caused by masking of the 
submucosal capillaries and increasing opacity of the 
mucosal surface[23]. As AA (pH 2.5­3.0) infiltrates 
through the multi­layered squamous epithelium it is 
neutralized, which protects the subepithelial stroma 
and vasculature[24]. In contrast, when sprayed on 
Barrett’s epithelium, at low concentrations (1%­3%), 
AA initially eliminates the superficial mucus layer 
by breakage of glycoprotein disulphide bonds. The 
unbuffered acid then causes a reversible acetylation 
of cellular proteins and a change in the spatial 
properties of nuclear and cytoplasmic proteins, initially 
causing an acetowhitening reaction that highlights 
the surface pattern (Figure 1). With the disruption 
of the mucus layer, AA reaches stromal capillaries 
causing vascular congestion, leading to focal erythema 
but this is hidden under the acetowhite mucosa and 
only becomes visible after the loss of acetowhitening 
(LAW). This focal redness due to LAW was first 
described, by the Portsmouth group in 2010[2], as a 
strong predictor of neoplasia. The exact mechanism 
remains unclear but it is believed that the difference 
in acetowhitening reaction between non­neoplastic 
and neoplastic mucosa is due to the difference in 
the nucleocytoplasmic ratio between non­neoplastic 
and neoplastic cells. The low cytoplasmic content of 
neoplastic cells allows them to lose acetowhitening 
quicker than non­neoplastic cells. This reaction leads 
to focal erythema ­ a pathognomic sign of neoplasia 
with AAC.
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ACETIC ACID FOR THE DIAGNOSIS 
OF NON-NEOPLASTIC BARRETT’S 
ESOPHAGUS
The diagnosis of Barrett’s esophagus, according to 
American society guidelines[25], is defined as the 
presence of esophageal IM. As IM is not readily 
identifiable by white light endoscopy, this diagnosis is 
made based on histology. Efforts have been made to 
visually identify IM by means of enhanced endoscopy. 
AA coupled with magnification endoscopy has been 
shown to accurately identify IM[21]. Guelrud et al[21] 
classified the surface pattern of Barrett’s mucosa into 
4 categories: (1) round pits; (2) reticular (circular or 
oval pits); (3) villous (fine villiform appearance without 
visible pits); and (4) ridged (thick villi with convoluted, 
cerebriform appearance without visible pits). 
They found that Pattern Ⅰ corresponded to fundic 
or cardiac type without IM and Patterns Ⅱ, Ⅲ, an Ⅳ 
each corresponded to IM with increasing sensitivities. 
The overall accuracy of AA with magnification en­
doscopy for the diagnosis of IM was 92.2%. These 
findings were reliably replicated by Toyoda et al[26] and 
Fortun et al[27].
A recent meta­analysis by Coletta et al[28] evaluated 
the use of AA for the detection of IM and HGD/EAC 
in patients with BE using histology as the reference 
standard. A total of 13 prospective studies (1690 
patients) were included in the meta­analysis. Eight of 
the 13 studies, provided data on the diagnosis of IM. 
For the characterization of IM, the pooled sensitivity, 
specificity, positive likelihood ratio (LR+), and negative 
likelihood ratio (LR­) for all the included studies (8 
studies, 516 patients) were 0.96 (95%CI: 0.83­0.99), 
0.69 (95%CI: 0.54­0.81), 3.0 (95%CI: 2.0­4.7) and 
0.06 (95%CI: 0.01­0.26), respectively. No significant 
sources of heterogeneity were identified on subgroup 
analysis. AA may be helpful for the exclusion of 
specialized IM, however, histological confirmation 
remains critical due to low specificity (0.69). In our 
view, this is clinically not relevant when dealing with 
long­segment BE as presence of specialized IM would 
not alter surveillance intervals.
ACETIC ACID IN THE DETECTION AND 
CHARACTERIZATION OF NEOPLASIA 
Use of AA to aid identification of IM in BE is important 
in the stratification of surveillance intervals[5]. However, 
the overriding utility of AA is the identification and 
characterization of Barrett’s neoplasia. There is a 
growing body of evidence to support the use of AA in 
this setting.
In 2006 Réaud et al[29], furthered Guelrud’s work 
aiming to define the neoplastic appearances of BE 
following 6% AA dye spray and magnification endoscopy. 
In their study of 28 patients, they noted that patients 
with HGD on biopsy displayed mucosal architectural 
disorganization and hypervascularity ­ a phenomenon 
previously identified by Rey et al[30] in 2003. Using these 
parameters, they demonstrated a positive predictive 
value (PPV) of 75% for neoplasia. Camus et al[31] 
identified similar features when combining AA with FICE.
In their study of 62 patients in 2006, Fortun et al[27] 
examined whether the combination of magnification 
endoscopy and 3% AA could improve diagnostic 
accuracy in patients with BE. Patients underwent 
a repeat endoscopy having recently undergone 
surveillance endoscopy (mean 7 mo prior). Barrett’s 
neoplasia was identified in 9 patients: 5 LGD, 1 HGD 
and 3 EAC. The main drawback from this study is that 
the index endoscopy was used as a control, raising 
the question as to whether the neoplasia detected was 
de-novo or previously missed, with the total number 
of neoplasias being small. At the same time, Yagi et 
al[32] reported that Barrett’s EAC was associated with 
an irregular granular pattern or a minute grain­like 
pattern following 1.5% AA dye spray and magnification 
endoscopy.
A year later Vázquez­Iglesias et al[33] reported on 
their prospective study of 100 patients undergoing 
Barrett’s surveillance, 13 of whom had neoplasia, 
using 3% AA and non­magnification endoscopy. 
They proposed the following mucosal classification: 
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Figure 1  Acetic acid mechanism of action. A: Non-dysplastic Barrett’s with HDWL; B: Non dysplastic BE following AAC (Olympus Lucera ELITE processor, 
GIFHQ290 gastroscope).
A B
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mL of simeticone, patients underwent conventional 
white light endoscopy followed by 2.5% AAC. The 
Barrett’s segment was assessed for the following 
features: (1) surface pattern: ridged, villous, round, 
irregular; (2) vascular pattern: regular or irregular; and 
(3) acetowhitening reaction: No loss of acetowhitening 
or focal early loss of acetowhitening.
Dysplastic Barrett’s was defined endoscopically as 
(Figure 2): (1) irregular surface patterns AND/OR; (2) 
increased vascularity or irregular vessels AND/OR; and 
(3) focal, early loss of acetowhitening was present. 
Targeted biopsies were performed followed by 
4QBS (unless area already sampled with targeted 
biopsy). Again, the combination of targeted and 
4QBS was used as the reference for final histological 
diagnosis.
Seventy­eight procedures were performed in 
patients with no prior neoplasia history (low­risk 
group) and 112 procedures were performed in patients 
referred with a history of neoplasia (high­risk group). 
Neoplasia was histologically confirmed in 88/190 
procedures: 21/88 EAC (T1a/b), 51/88 HGD, 16/88 
LGD. AAC targeted biopsy demonstrated a sensitivity 
of 95.5% and specificity 80% for neoplasia detection. 
Significant correlation between the in vivo diagnosis 
of neoplasia and final histology was noted (r = 0.98). 
There was a 2.5­fold increase in visible neoplasia 
detection with AAC as compared to white light alone 
(P = 0.001). The limitations of this study are similar 
to those of the Wiesbaden group: single center, expert 
endoscopist with a dysplasia­enriched population. 
What these studies cannot answer is how AAC would 
perform in the surveillance population where dysplasia 
prevalence is much lower and how AAC performs in 
non­expert hands.
Another factor limiting the use of AAC is the 
additional skills required to interpret surface and 
vascular patterns and their subjective nature. To 
that end the Portsmouth group sought to develop an 
objective tool using the duration of acetowhitening for 
the diagnosis of neoplasia[2]. One hundred and thirty­
two patients underwent 2.5% AAC with targeted 
(1) normal pattern: uniform reticulum along entire 
columnar­lined esophagus; and (2) abnormal pattern: 
rough or irregular reticulum. 
Applying these characteristics, they demonstrated 
100% sensitivity and 97.7% specificity (PPV 86% 
NPV 100%) for the detection of early neoplasia. with 
the false positives arising in 2 patients; one with 
esophagitis, the other with an esophageal ulcer.
These results were a significant improvement 
on those reported by Mayinger et al[34] in 2006 who 
reported sensitivities for neoplasia recognition in the 
range 55.5% to 82.4% in endoscopists trained in 
interpretation of AA enhanced magnification endoscopy. 
The same study also demonstrated extremely low inter­ 
and intra­observer agreement for the technique.
The Wiesbaden group first reported their ex­
periences of AAC for neoplasia detection in Barrett’s 
in 2007[35]. They performed a prospective randomized 
crossover tandem endoscopy study examining 57 
patients with a history of Barrett’s neoplasia with AAC 
or virtual chromoendoscopy, using Fujinon Intelligent 
Chromoendoscopy (FICE), 4­6 wk apart. The patients 
had a known history of Barrett’s neoplasia (discrete 
mucosal alteration/ macroscopically occult lesions/ 
prior endoscopic treatment for neoplasia). Targeted 
biopsy of visible abnormalities was performed along 
with 4QBS. In 24 patients neoplasia was identified 
with the AAC achieving an 87% sensitivity. There are 
however, limitations with this study in that combined 
biopsies (targeted plus 4QBS) were used as the 
reference standard not surgical resection specimens. 
The study population was neoplasia­enriched in a 
tertiary center and thus results may not reflect the true 
performance of AAC in the community, surveillance 
population.
Longcroft­Wheaton et al[36] from Portsmouth repor­
ted on their cohort of patients undergoing Barrett’s 
examination with AAC with strikingly similar results. 
The study design was similar to the Wiesbaden group 
with 190 procedures performed in 119 patients. After 
esophageal cleansing, with a 50 mL solution containing 
40 mL of water, 5 mL of 10% N­acetylcysteine and 5 
Figure 2  Dysplastic Barrett’s was defined endoscopically. A: Barrett’s with HDWL; B: Same patient note dysplasia only visible post AAC with early loss of 
acetowhitening (Olympus Lucera ELITE processor, GIFHQ290 gastroscope). 
A B
Chedgy FJQ et al . Acetic acid chromoendoscopy
5757 July 7, 2016|Volume 22|Issue 25|WJG|www.wjgnet.com
biopsies of neoplasia, followed by 4QBS. Time taken to 
lose acetowhitening effect was measured and analyzed 
for metaplasia, HGD and EAC. In cases of cancer, 
acetowhitening was lost in a median of 23 s (range 
3­81 s), for HGD the median was 53 s (range 4­288 
s). In non­dysplastic Barrett’s median time was 311 
s (range 14­992). They proved the concept of focal 
loss of acetowhitening (LAW) as a very effective tool 
in distinguishing metaplasia from HGD and HGD from 
EAC. The time differences to lose acetowhitening were 
statistically significant (P < 0.05). In order to further 
refine the tool, the authors plotted a receiver operating 
characteristic and determined that a time of 142 s 
yielded the optimum sensitivity of 98% and specificity 
of 84%. The benefit of this tool is that it provides 
endoscopists an objective measure of neoplasia, 
avoiding subjective interpretation of mucosal and 
vessel patterns. This is clinically very relevant as this 
phenomenon can be universally applied, regardless of 
endoscope manufacturer or definition, and requires 
minimal training. Their results reach the ASGE PIVI 
(preservation and incorporation of valuable endoscopic 
innovations) criteria[37] (sensitivity ≥ 90%, NPV ≥ 
98% and specificity > 80%), reaching these thresholds 
eliminates the need for random 4QBs.
In the meta­analysis by Coletta et al[28], 9 studies 
(1379 patients) looked at AAC for the diagnosis of 
HGD/EAC. The pooled sensitivity, specificity, LR+, 
LR­ was 0.92 (95%CI: 0.83­0.97), 0.96 (95%CI: 
0.85­0.99), 25.0(95%CI: 5.9­105.3) and 0.08 
(95%CI: 0.04­0.18), respectively. Subgroup analysis 
did not identify significant sources of heterogeneity. 
The results highlight, high sensitivity 92% and 
specificity 96% for AAC in the diagnosis of HGD/EAC. 
ACETIC ACID IN THE SURVEILLANCE 
POPULATION
The advent of advanced endoscopic imaging tech­
nologies such as NBI, FICE and i­scan have improved 
the identification and characterization of neoplastic 
lesions, but these technologies require significant 
financial investment. Therefore, the role of AA in 
the surveillance population is of great interest as a 
potentially cost­effective, accurate and non­proprietary 
tool for improving dysplasia detection.
Cost-effectiveness of acetic acid targeted biopsy 
protocols
In 2010 the Wiesbaden group published a much 
larger AAC series[38]. In their study they enrolled 701 
consecutive Barrett’s patients, 406 in a high­risk group 
(history of Barrett’s neoplasia) and 295 in a low­risk 
group (no history of neoplasia). Each patient was 
examined with high­resolution white light followed 
by 1.5% AAC. Targeted biopsy of visible lesions was 
performed followed by 4QBS every 1­2cm (unless area 
already sampled with targeted biopsy). To improve 
visibility during 4QBS of long segment Barrett’s the 
dry­biopsy technique[39] was employed ­ spraying 
1:20000 adrenaline onto the Barrett’s segment prior 
to biopsy. A total of 459 targeted biopsies were taken 
and 5485 4QBS. One hundred and thirty­two early 
neoplastic lesions (HGD/EAC) were identified in 92 
patients. AA was demonstrated to perform with a 
sensitivity of 96.7% and specificity of 66.5% overall 
with PPV 30.4% and NPV 99.3%. Only 3 additional 
patients (3.3%) with neoplasia were identified by 
4QBS in the high­risk group. Their data suggested that 
there was minimal additional yield of 4QBS over AA 
targeted biopsy for the detection of dysplasia with the 
mean number of targeted biopsies required to yield 
one diagnosis of neoplasia being 5.2 vs 1828 for 4QBS. 
However, all HGD and EAC detected in this series were 
from the high­risk group, limiting applicability in the 
low­risk surveillance population.
Bhandari et al[20] conducted a retrospective co­
hort study of all AAC procedures for BE performed 
from 2005­2010 to examine the efficacy and cost 
implications of this method in the identification of 
neoplasia. This study was done in a tertiary­center 
with all procedures being performed by a single expert 
endoscopist. High definition white light endoscopy 
(HDWL) was used in all cases prior to 2.5% AAC. 
Targeted biopsies of all AA­enhanced visible lesions 
were taken, followed by 4QBS. 197 high­risk patients 
underwent 263 procedures. Of these, 68 patients 
were referred with non­visible HGD on random 
biopsy. Notably, there was a high proportion of high­
risk neoplasia (HGD/EAC) in this cohort of patients 
(143/263 procedures; 54.4%). There was a twofold 
increase in neoplasia detection using AA (96%) as 
compared to HDWL (48%), P = 0.0001. HGD was 
missed with AA in 5/98 patients (5.1%) however, 4 of 
these were in the complex, post­EMR follow up group. 
They performed a cost modelling exercise of 3 
alternative biopsy sampling protocols incorporating AA 
using their mean length BE of 4.5cm (Table 1). There 
was a 4% neoplasia miss­rate in the AA­targeted 
biopsies alone group. Nevertheless, the cost saving 
calculated is significant in the context of the high­risk 
population included in this study and if applied to the 
usual surveillance population with a lower neoplasia 
prevalence rate of < 5%, cost­effectiveness increases 
10 fold. 
The Portsmouth group published another retro­
spective cohort study[40] comparing the neoplasia 
yield of AAC with 4QBS, in a routine BE surveillance 
population. Nine hundred and seventy­two patients 
were included in the study, with 655 (67%) undergoing 
4QBS and 327 (33%) AAC. A gain in neoplasia 
detection was demonstrated in the AAC group on both 
per patient and per biopsy analysis. A significant (P 
= 0.0001) gain from 2% neoplasia rates in the 4QBS 
group to 12.5% in the AAC group was noted. When 
analyzed per biopsy, a 14.7­fold increase in neoplasia 
detection was seen in the AAC group per biopsy 
Chedgy FJQ et al . Acetic acid chromoendoscopy
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compared to 4QBS (0.025 vs 0.0017, P < 0.05). The 
number of biopsies required to detect one neoplasia 
was 15 times lower in the AAC cohort compared to 
the 4QBS cohort (40 biopsies vs 604 biopsies). This 
study was the first of its kind in a Barrett’s surveillance 
population and demonstrates a proof of concept that 
can be used to power a randomized controlled trial 
comparing 4QBS with AAC. 
These data demonstrate that AAC targeted biopsy 
protocols are extremely cost­effective in high­risk 
populations and suggest even greater gains are to be 
expected in the surveillance population.
The Portsmouth group is currently underway with 
the ABBA study[41]. This is a multi­center randomized, 
crossover, tandem endoscopy study comparing 4QBS 
versus AA targeted biopsies, in a Barrett’s surveillance 
population. The study will also focus on training the 
AAC technique by a web­based training program 
utilizing a comprehensive and well­validated image 
and video library. The results of this study (expected 
to complete in 2016) will add to the growing evidence 
base on the use of AAC in the surveillance population.
CONCLUSION
The evidence for the use of AAC in the detection and 
characterization of Barrett’s neoplasia is compelling. 
The large studies from the Portsmouth and Wiesbaden 
groups demonstrate that experts are able to meet 
the ASGE PIVI criteria[40] (sensitivity ≥ 90%, NPV 
≥ 98% and specificity > 80%) and are thus able 
to justifiably dispense with 4QBS. The technique is 
cheap and can be universally applied, regardless 
of endoscope manufacturer. However, further data 
from a well­powered randomized controlled trial are 
required before completely abandoning 4QBS and 
it may be that the modified Portsmouth protocol 
provides optimum results for cost­effective Barrett’s 
surveillance.
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